Gilead Sciences, Inc. (GILD) Reaches $63.91 1 Year Low; Arrowpoint Asset Management Trimmed Its Diageo P L C (DEO) Stake

June 16, 2017 - By marketbeat

Arrowpoint Asset Management Llc decreased Diageo P L C (DEO) stake by 22.41% reported in 2016Q4 SEC filing. Arrowpoint Asset Management Llc sold 17,000 shares as Diageo P L C (DEO)’s stock rose 5.26%. The Arrowpoint Asset Management Llc holds 58,870 shares with $6.12M value, down from 75,870 last quarter. Diageo P L C now has $75.16 billion valuation. The stock rose 0.66% or $0.79 reaching $121.17. About 94,573 shares traded. Diageo plc (ADR) (NYSE:DEO) has risen 12.82% since June 16, 2016 and is uptrending. It has underperformed by 3.88% the S&P500.

The stock of Gilead Sciences, Inc. (NASDAQ:GILD) hit a new 52-week low and has $60.08 target or 6.00% below today’s $63.91 share price. The 8 months bearish chart indicates high risk for the $83.28B company. The 1-year low was reported on Jun, 16 by Barchart.com. If the $60.08 price target is reached, the company will be worth $5.00 billion less. About 4.12M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since June 16, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Gilead Sciences, Inc. is a research biopharmaceutical firm that discovers, develops and commercializes medicines in areas of unmet medical need. The company has market cap of $83.28 billion. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome , liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. It has a 6.76 P/E ratio. The Company’s products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta.

Since January 3, 2017, it had 0 insider purchases, and 11 sales for $33.68 million activity. 73,333 shares were sold by MARTIN JOHN C, worth $4.78 million. WILSON GAYLE E sold $1.41M worth of stock or 20,365 shares. Alton Gregg H sold 5,000 shares worth $325,114. $668,667 worth of stock was sold by Cogan John Francis on Tuesday, May 9.

Among 27 analysts covering Gilead Sciences (NASDAQ:GILD), 18 have Buy rating, 0 Sell and 9 Hold. Therefore 67% are positive. Gilead Sciences has $137 highest and $87 lowest target. $108.42’s average target is 69.64% above currents $63.91 stock price. Gilead Sciences had 65 analyst reports since July 29, 2015 according to SRatingsIntel. On Thursday, November 5 the stock rating was upgraded by Piper Jaffray to “Overweight”. On Thursday, September 22 the stock rating was initiated by Berenberg with “Buy”. The firm has “Neutral” rating given on Friday, January 15 by Bank of America. On Friday, February 5 the stock rating was initiated by Leerink Swann with “Outperform”. The rating was maintained by Maxim Group with “Buy” on Friday, February 12. The company was initiated on Wednesday, February 3 by Standpoint Research. Vetr upgraded the stock to “Buy” rating in Monday, August 17 report. Jefferies maintained the stock with “Hold” rating in Wednesday, August 31 report. Maxim Group maintained the shares of GILD in report on Tuesday, May 30 with “Hold” rating. Credit Suisse maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, February 3. Credit Suisse has “Outperform” rating and $118 target.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 24. They expect $2.13 earnings per share, down 29.70% or $0.90 from last year’s $3.03 per share. GILD’s profit will be $2.78B for 7.50 P/E if the $2.13 EPS becomes a reality. After $2.20 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -3.18% negative EPS growth.

Investors sentiment decreased to 0.7 in 2016 Q4. Its down 0.23, from 0.93 in 2016Q3. It dived, as 106 investors sold Gilead Sciences, Inc. shares while 656 reduced holdings. 111 funds opened positions while 421 raised stakes. 950.84 million shares or 0.69% more from 944.29 million shares in 2016Q3 were reported. Earnest Prtn Ltd Liability Company holds 631 shares or 0% of its portfolio. Exchange Capital Mngmt accumulated 240 shares or 0.01% of the stock. Noesis Mangement Corporation holds 3.23% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 108,139 shares. Estabrook Cap Mngmt invested in 0% or 3,940 shares. Bragg Fincl Incorporated, a North Carolina-based fund reported 20,904 shares. Neville Rodie Shaw owns 75,506 shares. Madison Incorporated reported 0.32% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Ww Asset Mgmt owns 122,500 shares. Arrowgrass Capital Prtnrs (Us) Ltd Partnership owns 71,096 shares. Quinn Opportunity Lc has 0.27% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 12,400 shares. Crow Point Prns Ltd Liability Corp owns 0.01% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 1,029 shares. Moreover, Stifel has 0.36% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 1.18 million shares. Wesbanco Savings Bank Incorporated has invested 0.11% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Ftb Advsrs holds 0.64% in Gilead Sciences, Inc. (NASDAQ:GILD) or 64,276 shares. 1.72 million were accumulated by Great West Life Assurance Can.

Among 23 analysts covering Diageo (NYSE:DEO), 14 have Buy rating, 3 Sell and 6 Hold. Therefore 61% are positive. Diageo had 31 analyst reports since July 31, 2015 according to SRatingsIntel. Sterne Agee CRT initiated the shares of DEO in report on Tuesday, July 21 with “Buy” rating. The firm has “Hold” rating by Stifel Nicolaus given on Tuesday, January 12. The company was downgraded on Friday, March 31 by Goldman Sachs. The firm has “Buy” rating given on Thursday, October 1 by UBS. The company was upgraded on Wednesday, October 26 by HSBC. The rating was downgraded by Liberum Capital on Monday, January 30 to “Sell”. The company was downgraded on Thursday, May 25 by Citigroup. The stock has “Buy” rating by Deutsche Bank on Friday, July 31. The company was reinitiated on Friday, September 16 by Bank of America. The company was upgraded on Tuesday, June 28 by Goldman Sachs.

Arrowpoint Asset Management Llc increased Spectranetics Corp (NASDAQ:SPNC) stake by 606,614 shares to 2.60 million valued at $63.75 million in 2016Q4. It also upped Actua Corp (NASDAQ:ACTA) stake by 149,918 shares and now owns 738,481 shares. Merit Med Sys Inc (NASDAQ:MMSI) was raised too.